Clinical Procedures to Support Research in ALS
Launched by UNIVERSITY OF MIAMI · Apr 4, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The CAPTURE study is a research project aimed at understanding more about amyotrophic lateral sclerosis (ALS) and similar conditions. By looking at information collected from patients' medical records, researchers hope to gain insights that could help improve care and treatment for ALS and related disorders like primary lateral sclerosis and progressive muscular atrophy. This study is currently recruiting participants, and anyone aged 65 to 74 who has been diagnosed with ALS or a related disorder and is receiving care at a specific clinical center may be eligible to join.
To participate, individuals must be able and willing to give their consent, or a designated person can provide consent for them. However, those who cannot understand English or Spanish will not be able to participate. If you join the study, you can expect your medical information to be used in a way that helps researchers learn more about these diseases, potentially benefiting future patients. It's an opportunity to contribute to important research while receiving care at a participating center.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of ALS or a related disorder (e.g. primary lateral sclerosis, progressive muscular atrophy).
- • Receiving care at a clinical center that uses Epic as its EHR.
- • Able and willing to provide informed consent (or informed consent obtainable from a designated proxy).
- Exclusion Criteria:
- • Inability to understand English and/or Spanish
About University Of Miami
The University of Miami, a leading academic institution, is dedicated to advancing medical research and improving patient care through innovative clinical trials. With a commitment to excellence in education and research, the university fosters collaboration among multidisciplinary teams to explore new therapies and treatment modalities. Its extensive clinical programs are supported by state-of-the-art facilities and a diverse patient population, enabling the exploration of cutting-edge solutions to complex health challenges. The University of Miami is poised to contribute significantly to the field of medicine through its rigorous scientific inquiry and a steadfast commitment to ethical research practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Durham, North Carolina, United States
Winston Salem, North Carolina, United States
New York, New York, United States
Minneapolis, Minnesota, United States
Palo Alto, California, United States
Miami, Florida, United States
San Francisco, California, United States
Irvine, California, United States
Kansas City, Kansas, United States
New York City, New York, United States
Portland, Oregon, United States
San Antonio, Texas, United States
Patients applied
Trial Officials
Michael Benatar, MBChB, MS, DPhil
Principal Investigator
University of Miami
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials